Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGA9X0)

Drug Name
Sodium nitroprusside Drug Info
Synonyms
Nitroprusside (Sodium); Sodium nitroprusside anhydrous; 14402-89-2; C5FeN6O.2Na; Nitropruss; Nitroprusid-natrium; Sodium nitroprussate; Nitroprussidnatrium [German]; C5FeN6O.2H2O.2Na; Sodium nitroprusside [USAN]; Na2[Fe(CN)5(NO)]; Sodium nitroprussiate dihydrate; Sodium nitrosylpentacyanoferrate; SCHEMBL3020702; CCRIS 1912; Sodium Nitroprusside (anhydrous); Disodium nitrosylpentacyanoferrate; Disodium pentacyanonitrosylferrate; CHEBI:29321; Nitroprussiate de sodium [French]; MolPort-003-926-312; disodium pentacyanidonitrosylfer
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Cross-matching ID
PubChem CID
11953895
ChEBI ID
CHEBI:9179
CAS Number
CAS 13755-38-9
TTD Drug ID
DMGA9X0
ACDINA Drug ID
D01432

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Soluble guanylate cyclase (GCS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [2]
Nitroglycerin DMQ2491 Angina pectoris BA40 Approved [3]
IW-1973 DMK2T7J Heart failure BD10-BD13 Phase 2 [4]
CTI-1601 DMM4JMB Friedreich's ataxia 8A03.10 Phase 2 [5]
Runcaciguat DMCFTTN Chronic kidney disease GB61 Phase 2 [6]
MK-5475 DMIIZ4R Pulmonary arterial hypertension BB01.0 Phase 2 [7]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [8]
CY6463 DM84AVQ Alzheimer disease 8A20 Phase 2 [9]
(5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Soluble guanylate cyclase (GCS) TT23PYC GCYA1_HUMAN; GCYB1_HUMAN Modulator [1]

References

1 Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805.
2 Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C.
3 Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases. Front Pharmacol. 2021 May 24;12:656561.
6 Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379.
7 Effects of an inhaled soluble guanylate cyclase (sGC) stimulator MK-5475 in pulmonary arterial hypertension (PAH). Respir Med. 2023 Jan;206:107065.
8 First-in-human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS-penetrant soluble guanylyl cyclase stimulator. Clin Transl Sci. 2023 Aug;16(8):1381-1395.
9 Clinical pipeline report, company report or official report of Cyclerion Therapeutics